Co-Founder and CEO at Owlstone Medical Ltd.
Billy Boyle is an engineering graduate from Cambridge University. He is one of the original co-founders of Owlstone Inc, spun out of Cambridge in 2004, which has raised $28M in investment and won >$25M in defence contracts. He initially worked with silicon foundries in the design and fabrication of the core microchip technology and is co-inventor on 19 patents. He then assumed a commercial role with P&L responsibility for the Scientific Instruments and Industrial business units; responsible for sales of FAIMS products and contracts with >150 clients globally, including Agilent, Thermo, Roche Diagnostics, Samsung, GSK, 4D Pharma, Mayo Clinic and the NHS.
Billy started to focus on the medical applications of FAIMS technology after his wife, Kate, was diagnosed and later died of colon cancer as a result of a late diagnosis. He worked closely with clinical partners who integrated FAIMS technology across a broad spectrum of clinical trials in cancer, inflammatory disease & infectious disease.
Visit website: https://www.owlstonemedical.com/about/team/billy-boyle/
See also: Owlstone Medical - Company focused to development of non-invasive diagnostics for cancer and inflammatory diseases.
Billy Boyle News
Owlstone Medical raised $58M to advance its breath biopsy technology
FierceBiotech - 07-Sep-2021
Developing painless tests to detect lung cancer, liver diseases, respiratory diseases, and gut healthRead more...
Cancer breathalyser starts clinical trial for wide range of cancers
Guardian - 03-Jan-2019
VOCs in breath captured by mask sent to lab for diagnosis - avoids invasive testsRead more...
Lung cancer breath test trialled
BBC - 14-Feb-2015
Clinically trials planned for this yearRead more...